Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02962661 |
Recruitment Status :
Recruiting
First Posted : November 11, 2016
Last Update Posted : October 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiomyopathy Heart Failure | Other: Best Practice Other: Laboratory Biomarker Analysis Biological: Mesenchymal Stem Cell Transplantation | Phase 1 |
PRIMARY OBJECTIVE:
I. To demonstrate the safety of allogeneic human mesenchymal stem cells (hMSCs) administered by intravenous infusion and transendocardial injection in patients with left ventricular (LV) dysfunction and heart failure secondary to chemotherapy with anthracyclines.
SECONDARY OBJECTIVE:
I. To demonstrate the efficacy of allogeneic hMSCs administered by intravenous infusion and transendocardial injection in patients with left ventricular dysfunction (left ventricular ejection fraction [LVEF] < 40%) and heart failure secondary to treatment with anthracyclines.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive hMSCs intravenously (IV) over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive standard of care treatment for heart failure.
After completion of study treatment, patients are followed up periodically.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 72 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized 3-Arm Trial With Standard of Care Alone vs Either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Plus Standard of Care in Patients With Anthracycline-Associated Cardiomyopathy |
Actual Study Start Date : | July 18, 2020 |
Estimated Primary Completion Date : | July 30, 2023 |
Estimated Study Completion Date : | July 30, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm I (hMSCs IV)
Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
|
Other: Best Practice
Given standard of care
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Biological: Mesenchymal Stem Cell Transplantation intravenous infusion (IV) |
Experimental: Arm II (hMSCs transendocardially)
Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
|
Other: Best Practice
Given standard of care
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Biological: Mesenchymal Stem Cell Transplantation transendocardially (injection) |
Active Comparator: Arm III (standard of care)
Patients receive standard of care treatment for heart failure.
|
Other: Best Practice
Given standard of care
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies |
- Incidence of adverse events [ Time Frame: Up to 6 months ]Statistical analyses of safety will be descriptive.
- Change in left ventricular ejection fraction (LVEF) [ Time Frame: Baseline to 6 months ]The comparison will be between the two groups of patients.
- Change in improvement of left ventricular (LV) systolic function as assessed by LVEF [ Time Frame: Baseline up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.
- LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography [ Time Frame: Up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.
- Cardiac death [ Time Frame: Up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.
- Re-hospitalization after heart failure [ Time Frame: Up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.
- Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing [ Time Frame: Up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.
- Nonfatal myocardial infarction [ Time Frame: Up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.
- Revascularization [ Time Frame: Up to 6 months ]As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with LVEF =< 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy
- Documented New York Heart Association (NYHA) class I, II and III
- Patients with persistent LV dysfunction 90 days after discontinuation of trastuzumab
- Able to perform a 6 minute walk test.
- Been treated with appropriate maximal medical therapy for heart failure
- Patient or legally authorized representative able to sign informed consent
Exclusion Criteria:
- Evidence of ischemic heart disease as determined by study cardiologist
- Significant valvular disease; (aortic stenosis [AS] with aortic valve area [AVA] < 1.5 and severe aortic regurgitation [AR] and mitral regurgitation [MR])
- History of familial cardiomyopathy
- Recent documented myocarditis within 2 months of enrollment
- History of infiltrative cardiomyopathy or restrictive cardiomyopathy
- Estimated glomerular filtration rate (eGFR) < 50 by Mayo or Cockcroft formula.
- Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram
- Liver function tests > 3 x upper limit of normal
- NYHA class IV heart failure.
- Inotropic dependence
- Unstable or life-threatening arrhythmia
- Coagulopathy international normalized ratio (INR) > 1.5.
- Mechanical or bioprosthetic heart valve.
- Cardiogenic shock.
- Breastfeeding and/or pregnant women.
- Autoimmune disorders on current immunosuppressive therapy
- Active infection not responding to appropriate therapy as determined by study chair.
- Trastuzumab treatment within the last 3 months
- Automatic implantable cardioverter defibrillator (AICD) placement within the last 30 days
- AICD firing within the last 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02962661
Contact: Amanda L. Olson, MD | 713-745-1505 | alolson@mdanderson.org |
United States, Texas | |
M D Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Amanda Olson 713-745-3055 | |
Principal Investigator: Amanda Olson |
Principal Investigator: | Amanda Olson | M.D. Anderson Cancer Center |
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT02962661 |
Other Study ID Numbers: |
2015-0835 NCI-2016-01921 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2015-0835 ( Other Identifier: M D Anderson Cancer Center ) P30CA016672 ( U.S. NIH Grant/Contract ) |
First Posted: | November 11, 2016 Key Record Dates |
Last Update Posted: | October 8, 2021 |
Last Verified: | September 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Heart Failure Cardiomyopathies Heart Diseases Cardiovascular Diseases |